Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are emerging anti-diabetic drugs that normalize hyperglycemia by blocking renal proximal tubular glucose reabsorption [17]. This evidence concerns the gene SLC5A2 and Hyperglycemia.